LUPIN - IntraDay Trade Analysis with Live Signals
Back to ListIntraDay Trade Rating: 4.2
| Stock Code | LUPIN | Market Cap | 1,05,389 Cr. | Current Price | 2,305 ₹ | High / Low | 2,381 ₹ |
| Stock P/E | 19.1 | Book Value | 596 ₹ | Dividend Yield | 0.52 % | ROCE | 21.9 % |
| ROE | 17.8 % | Face Value | 2.00 ₹ | DMA 50 | 2,285 ₹ | DMA 200 | 2,146 ₹ |
| Chg in FII Hold | 0.20 % | Chg in DII Hold | -0.26 % | PAT Qtr | 1,241 Cr. | PAT Prev Qtr | 869 Cr. |
| RSI | 49.5 | MACD | 4.44 | Volume | 11,11,629 | Avg Vol 1Wk | 10,25,500 |
| Low price | 1,837 ₹ | High price | 2,381 ₹ | PEG Ratio | 0.11 | Debt to equity | 0.04 |
| 52w Index | 86.1 % | Qtr Profit Var | 18.6 % | EPS | 120 ₹ | Industry PE | 30.1 |
📈 Optimal Buy Price
Entry zone: ₹2,295–₹2,310, near 50 DMA support. Avoid chasing above ₹2,325 unless volume expands beyond weekly average.
🎯 Exit Levels
- Profit-taking: ₹2,345–₹2,360 if momentum sustains
- Stop-loss: Below ₹2,280 (weakness under DMA support)
⏳ Intraday Exit Guidance
If already holding, consider exiting if RSI dips below 47, price fails to hold above ₹2,295, or volume momentum fades below 9.5 lakh with stagnant price action. Book profits near ₹2,345–₹2,360 if momentum slows.
✅ Positive
Strong quarterly PAT growth (₹869 Cr. → ₹1,241 Cr.), EPS at ₹120 reflects robust earnings, ROE (17.8%) and ROCE (21.9%) show healthy returns, FII holdings increased (+0.20%), and PEG ratio at 0.11 indicates undervaluation relative to growth.
⚠️ Limitation
DII holdings decreased (-0.26%), RSI at 49.5 shows neutral strength limiting aggressive upside, and stock trading close to resistance zone (₹2,381).
📉 Company Negative News
Decline in domestic institutional participation and risk of profit booking near 52-week high levels.
📊 Company Positive News
Sequential PAT growth of 18.6%, breakout above DMA 50 and DMA 200 confirms technical strength, and valuation discount compared to industry peers (P/E 19.1 vs 30.1).
🏭 Industry
Pharma sector average P/E at 30.1, Lupin trades at a discount (19.1). Sector outlook supported by global demand for generics and specialty drugs.
🔎 Conclusion
Lupin is a strong intraday candidate with valuation comfort, earnings strength, and momentum support. Best suited for entries near ₹2,295–₹2,310 with exits around ₹2,345–₹2,360. Maintain strict stop-loss discipline below ₹2,280 to protect against intraday reversals.